An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery - PubMed (original) (raw)

. 2024 Jun 14;384(6701):1220-1227.

doi: 10.1126/science.adm8386. Epub 2024 May 16.

Ken Y Chan # 1, Jason Wu 1, Nuria R Botticello-Romero 1, Qingxia Zheng 1, Shan Lou 1, Casey Keyes 1, Alexander Svanbergsson 1, Jencilin Johnston 1, Allan Mills 1, Chin-Yen Lin 1, Pamela P Brauer 1, Gabrielle Clouse 1, Simon Pacouret 1, John W Harvey 1, Thomas Beddow 1, Jenna K Hurley 1, Isabelle G Tobey 1, Megan Powell 1, Albert T Chen 1, Andrew J Barry 1, Fatma-Elzahraa Eid 1 2, Yujia A Chan 1, Benjamin E Deverman 1

Affiliations

An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery

Qin Huang et al. Science. 2024.

Abstract

Developing vehicles that efficiently deliver genes throughout the human central nervous system (CNS) will broaden the range of treatable genetic diseases. We engineered an adeno-associated virus (AAV) capsid, BI-hTFR1, that binds human transferrin receptor (TfR1), a protein expressed on the blood-brain barrier. BI-hTFR1 was actively transported across human brain endothelial cells and, relative to AAV9, provided 40 to 50 times greater reporter expression in the CNS of human TFRC knockin mice. The enhanced tropism was CNS-specific and absent in wild-type mice. When used to deliver GBA1, mutations of which cause Gaucher disease and are linked to Parkinson's disease, BI-hTFR1 substantially increased brain and cerebrospinal fluid glucocerebrosidase activity compared with AAV9. These findings establish BI-hTFR1 as a potential vector for human CNS gene therapy.

PubMed Disclaimer

Update of

Similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources